📊 EOLS Key Takeaways
Is Evolus, Inc. (EOLS) a Good Investment?
Evolus is a financially distressed pharmaceutical company with negative stockholders' equity of -$23.1M, indicating liabilities exceed assets. Despite 11.6% revenue growth to $297.2M, the company is burning cash with -$45.7M free cash flow and cannot achieve profitability with a -17.4% net margin. The company faces an existential solvency risk given negative equity, negative operating cash flow, and $146.1M in long-term debt against only $53.8M in cash.
Evolus is showing solid top-line growth and healthy gross margins, which suggests its core product economics remain attractive. However, that revenue growth is not translating into operating profitability or cash generation, and the combination of recurring losses, negative free cash flow, high leverage, and negative equity materially weakens the fundamental picture. Until margin improvement and cash flow stabilization become clear, the business looks financially stretched rather than fundamentally strong.
Why Buy Evolus, Inc. Stock? EOLS Key Strengths
- Revenue growth of 11.6% YoY demonstrates market demand for products
- Strong gross margin of 66.3% indicates pricing power and product profitability at contribution level
- Current ratio of 1.90x suggests near-term liquidity to cover immediate obligations
- Revenue grew 11.6% year over year, indicating continued commercial demand
- Gross margin of 66.3% shows strong underlying product economics
- Current ratio of 1.90x and quick ratio of 1.54x indicate acceptable near-term liquidity
EOLS Stock Risks: Evolus, Inc. Investment Risks
- Negative stockholders' equity of -$23.1M indicates technical insolvency and potential covenant violations
- Operating cash flow negative at -$42.3M with free cash flow of -$45.7M; company is depleting cash reserves unsustainably
- Operating loss of -$32.7M on $297.2M revenue indicates inability to convert gross profit to operational earnings despite revenue growth
- Long-term debt of $146.1M with only $53.8M cash and negative operating cash flow creates debt service risk
- Net loss of -$51.6M indicates cash burn accelerating beyond operating losses due to interest and other charges
- Operating margin of -11.0% and net margin of -17.4% show the company is still structurally unprofitable
- Negative operating cash flow and free cash flow indicate growth is not yet self-funding
- Negative stockholders equity, $146.10M of long-term debt, and negative interest coverage point to elevated balance sheet risk
Key Metrics to Watch
- Operating cash flow trajectory and path to positive FCF generation
- Stockholders' equity recovery and solvency status
- Ability to service $146.1M long-term debt with deteriorating cash position
- Operating margin improvement and timeline to profitability at EBIT level
- Cash burn rate and months of cash remaining at current depletion rates
- Operating cash flow and free cash flow trend
- Operating margin improvement relative to revenue growth
Evolus, Inc. (EOLS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Evolus, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
EOLS Profit Margin, ROE & Profitability Analysis
EOLS vs Healthcare Sector: How Evolus, Inc. Compares
How Evolus, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Evolus, Inc. Stock Overvalued? EOLS Valuation Analysis 2026
Based on fundamental analysis, Evolus, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Evolus, Inc. Balance Sheet: EOLS Debt, Cash & Liquidity
EOLS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Evolus, Inc.'s revenue has grown significantly by 198% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.08 indicates the company is currently unprofitable.
EOLS Revenue Growth, EPS Growth & YoY Performance
EOLS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $61.1M | -$11.4M | $-0.24 |
| Q2 2025 | $66.9M | -$11.4M | $-0.18 |
| Q1 2025 | $59.3M | -$13.1M | $-0.22 |
| Q3 2024 | $50.0M | -$11.4M | $-0.30 |
| Q2 2024 | $49.3M | -$11.4M | $-0.18 |
| Q1 2024 | $41.7M | -$13.1M | $-0.22 |
| Q3 2023 | $33.9M | -$14.8M | $-0.30 |
| Q2 2023 | $37.2M | -$14.8M | $-0.32 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Evolus, Inc. Dividends, Buybacks & Capital Allocation
EOLS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Evolus, Inc. (CIK: 0001570562)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EOLS
What is the AI rating for EOLS?
Evolus, Inc. (EOLS) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EOLS's key strengths?
Claude: Revenue growth of 11.6% YoY demonstrates market demand for products. Strong gross margin of 66.3% indicates pricing power and product profitability at contribution level. ChatGPT: Revenue grew 11.6% year over year, indicating continued commercial demand. Gross margin of 66.3% shows strong underlying product economics.
What are the risks of investing in EOLS?
Claude: Negative stockholders' equity of -$23.1M indicates technical insolvency and potential covenant violations. Operating cash flow negative at -$42.3M with free cash flow of -$45.7M; company is depleting cash reserves unsustainably. ChatGPT: Operating margin of -11.0% and net margin of -17.4% show the company is still structurally unprofitable. Negative operating cash flow and free cash flow indicate growth is not yet self-funding.
What is EOLS's revenue and growth?
Evolus, Inc. reported revenue of $297.2M.
Does EOLS pay dividends?
Evolus, Inc. does not currently pay dividends.
Where can I find EOLS SEC filings?
Official SEC filings for Evolus, Inc. (CIK: 0001570562) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EOLS's EPS?
Evolus, Inc. has a diluted EPS of $-0.80.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EOLS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Evolus, Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EOLS stock overvalued or undervalued?
Valuation metrics for EOLS: ROE of N/A (sector avg: 15%), net margin of -17.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EOLS stock in 2026?
Our dual AI analysis gives Evolus, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EOLS's free cash flow?
Evolus, Inc.'s operating cash flow is $-42.3M, with capital expenditures of $3.4M. FCF margin is -15.4%.
How does EOLS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -17.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.90 (avg: 2).